

Christina Binder

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/507532/publications.pdf>

Version: 2024-02-01

87
papers

6,072
citations

147801
31
h-index

74163
75
g-index

89
all docs

89
docs citations

89
times ranked

9284
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis. Heart, 2022, 108, 1137-1147.	2.9	9
2	Tafamidis treatment delays structural and functional changes of the left ventricle in patients with transthyretin amyloid cardiomyopathy. European Heart Journal Cardiovascular Imaging, 2022, 23, 767-780.	1.2	38
3	OUP accepted manuscript. European Heart Journal Cardiovascular Imaging, 2022, , .	1.2	0
4	Cardiac remodeling in ambitious endurance-trained amateur athletes older than 50 yearsâ€“an observational study. PLoS ONE, 2022, 17, e0266951.	2.5	1
5	Effects of omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 5006-5016.	2.2	15
6	A machine learning algorithm supports ultrasound-naïve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. International Journal of Cardiovascular Imaging, 2021, 37, 577-586.	1.5	37
7	Sex differences in arrhythmic burden with the wearable cardioverter-defibrillator. Heart Rhythm, 2021, 18, 404-410.	0.7	10
8	The COVID-19 burden for health care professionals: Results of a global survey. European Journal of Internal Medicine, 2021, 83, 96-98.	2.2	12
9	How to <sc>ATTR&ACT</sc> the perfect match?. European Journal of Heart Failure, 2021, 23, 275-276.	7.1	2
10	Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clinical Research in Cardiology, 2021, 110, 532-543.	3.3	21
11	Renin Feedback Is an Independent Predictor of Outcome in HFpEF. Journal of Personalized Medicine, 2021, 11, 370.	2.5	7
12	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology, 2021, 78, 97-108.	2.8	73
13	Diagnosis and supportive therapeutic management of cardiac light chain amyloidosisâ€“a cardiologistâ€™s perspective. Memo - Magazine of European Medical Oncology, 2021, 14, 89-97.	0.5	4
14	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	4.1	5
15	Convolutional Neural Networks for Fully Automated Diagnosis of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging. Journal of Personalized Medicine, 2021, 11, 1268.	2.5	5
16	Determinants of Bioprosthetic Aortic Valve Degeneration. JACC: Cardiovascular Imaging, 2020, 13, 345-353.	5.3	27
17	Native T1 time of right ventricular insertion points by cardiac magnetic resonance: relation with invasive haemodynamics and outcome in heart failure with preserved ejection fraction. European Heart Journal Cardiovascular Imaging, 2020, 21, 683-691.	1.2	22
18	Persistent atrial fibrillation in heart failure with preserved ejection fraction: Prognostic relevance and association with clinical, imaging and invasive haemodynamic parameters. European Journal of Clinical Investigation, 2020, 50, e13184.	3.4	10

#	ARTICLE	IF	CITATIONS
19	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
20	What Type of Patients Did PARAGON-HF Select? Insights from a Real-World Prospective Cohort of Patients with Heart Failure and Preserved Ejection Fraction. Journal of Clinical Medicine, 2020, 9, 3669.	2.4	7
21	Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wiener Klinische Wochenschrift, 2020, 132, 742-761.	1.9	31
22	Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots. Journal of Clinical Medicine, 2020, 9, 2234.	2.4	10
23	In Vivo Quantification of Myocardial Amyloid Deposits in Patients with Suspected Transthyretin-Related Amyloidosis (ATTR). Journal of Clinical Medicine, 2020, 9, 3446.	2.4	19
24	Machine Learning Enables Prediction of Cardiac Amyloidosis by Routine Laboratory Parameters: A Proof-of-Concept Study. Journal of Clinical Medicine, 2020, 9, 1334.	2.4	13
25	Low serum potassium levels and diabetes - An unfavorable combination in patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2020, 317, 121-127.	1.7	4
26	Feature Tracking of Global Longitudinal Strain by Using Cardiovascular MRI Improves Risk Stratification in Heart Failure with Preserved Ejection Fraction. Radiology, 2020, 296, 290-298.	7.3	34
27	Lightâ€chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. European Journal of Heart Failure, 2020, 22, 1852-1862.	7.1	82
28	Hemodynamic Profiles and Their Prognostic Relevance in Cardiac Amyloidosis. Journal of Clinical Medicine, 2020, 9, 1093.	2.4	6
29	Decline in physical activity in the weeks preceding sustained ventricular arrhythmia in women. Heart Rhythm O2, 2020, 1, 283-287.	1.7	4
30	Patients with Heart Failure and Preserved Ejection Fraction Are at Risk of Gastrointestinal Bleeding. Journal of Clinical Medicine, 2019, 8, 1240.	2.4	11
31	Angs (Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction. Hypertension, 2019, 74, 285-294.	2.7	26
32	Visual assessment of right ventricular function by echocardiography: how good are we?. International Journal of Cardiovascular Imaging, 2019, 35, 2001-2008.	1.5	23
33	Riociguat for the treatment of transthyretin cardiac amyloidosis: data from a named patient use program in Austria. Pulmonary Circulation, 2019, 9, 1-9.	1.7	1
34	Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgeryâ€. European Journal of Cardio-thoracic Surgery, 2019, 56, 534-540.	1.4	12
35	Serum levels of gamma-glutamyltransferase predict outcome in heart failure with preserved ejection fraction. Scientific Reports, 2019, 9, 18541.	3.3	10
36	Echocardiographic assessment of right ventricular function: current clinical practice. International Journal of Cardiovascular Imaging, 2019, 35, 49-56.	1.5	53

#	ARTICLE	IF	CITATIONS
37	Syncope. JACC: Cardiovascular Imaging, 2019, 12, 225-232.	5.3	22
38	Diagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging in Aortic Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1474-1483.	5.3	59
39	Mechanisms of heart failure in transthyretin vs. light chain amyloidosis. European Heart Journal Cardiovascular Imaging, 2019, 20, 512-524.	1.2	26
40	Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping. Scientific Reports, 2018, 8, 5572.	3.3	17
41	Gender-related differences in heart failure with preserved ejection fraction. Scientific Reports, 2018, 8, 1080.	3.3	60
42	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2471-2476.	0.8	39
43	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Annals of the Rheumatic Diseases, 2018, 77, 128-132.	0.9	20
44	Extracellular volume quantification by cardiac magnetic resonance imaging without hematocrit sampling. Wiener Klinische Wochenschrift, 2018, 130, 190-196.	1.9	18
45	FP539IMPACT OF SYSTEMIC VOLUME STATUS ON CARDIAC MAGNETIC RESONANCE T1 MAPPING IN HEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2018, 33, i221-i221.	0.7	0
46	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. Scientific Reports, 2018, 8, 9372.	3.3	39
47	Development and validation of a TTR-specific copy number screening tool, and application to potentially relevant patient cohorts. Molecular and Cellular Probes, 2018, 41, 61-63.	2.1	0
48	Cardiac Magnetic Resonance T1 Mapping in Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 2018, 11, 1924-1926.	5.3	34
49	Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. European Heart Journal, 2017, 38, ehw597.	2.2	83
50	Fluid status and outcome in patients with heart failure and preserved ejection fraction. International Journal of Cardiology, 2017, 230, 476-481.	1.7	26
51	Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis. Kidney and Blood Pressure Research, 2017, 42, 165-176.	2.0	1,821
52	Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. European Journal of Heart Failure, 2017, 19, 502-511.	7.1	17
53	Diameter of the Pulmonary Artery in Relation to the Ascending Aorta: Association with Cardiovascular Outcome. Radiology, 2017, 284, 685-693.	7.3	11
54	Artificial intelligence in cardiology. Wiener Klinische Wochenschrift, 2017, 129, 866-868.	1.9	20

#	ARTICLE	IF	CITATIONS
55	Wedge Pressure Rather Than Left Ventricular End-Diastolic Pressure Predicts Outcome in Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 795-801.	4.1	58
56	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	13
57	Preserved right ventricular integrity in a new telemetric rat model of severe pulmonary hypertension. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2017, 313, L957-L963.	2.9	2
58	Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 34, 695-700.	1.5	13
59	Modes of death in patients with heart failure and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2017, 228, 422-426.	1.7	42
60	Presence of isolated tricuspid regurgitation should prompt the suspicion of heart failure with preserved ejection fraction. <i>PLoS ONE</i> , 2017, 12, e0171542.	2.5	34
61	Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 978-980.	1.2	10
62	Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2016, 68, 189-199.	2.8	77
63	Interstitial Fibrosis, Functional Status, and Outcomes in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	2.6	113
64	Cardiac arrest does not affect survival in post-operative cardiovascular surgery patients undergoing extracorporeal membrane oxygenation. <i>Resuscitation</i> , 2016, 104, 24-27.	3.0	22
65	Evaluation of the pharmacodynamic effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 882-889.	1.9	20
66	The right heart in heart failure with preserved ejection fraction: insights from cardiac magnetic resonance imaging and invasive haemodynamics. <i>European Journal of Heart Failure</i> , 2016, 18, 71-80.	7.1	114
67	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2016, 18, 89-93.	7.1	43
68	Riociguat for the treatment of pulmonary hypertension: a safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1671-1677.	2.4	6
69	Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery. <i>Critical Care</i> , 2016, 20, 57.	5.8	46
70	T1 Mapping by CMR Imaging. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 14-23.	5.3	164
71	Impaired antioxidant HDL function is associated with premature myocardial infarction. <i>European Journal of Clinical Investigation</i> , 2015, 45, 731-738.	3.4	21
72	Prognostic Significance and Determinants of the 6-Min Walk Test in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 459-466.	4.1	48

#	ARTICLE	IF	CITATIONS
73	Pulmonary artery to aorta ratio for the detection of pulmonary hypertension: cardiovascular magnetic resonance and invasive hemodynamics in heart failure with preserved ejection fraction. Journal of Cardiovascular Magnetic Resonance, 2015, 17, 79.	3.3	43
74	Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. PLoS ONE, 2015, 10, e0134479.	2.5	26
75	Prognostic Impact of Tricuspid Regurgitation in Patients Undergoing Aortic Valve Surgery for Aortic Stenosis. PLoS ONE, 2015, 10, e0136024.	2.5	28
76	Right Ventricular Dysfunction, But Not Tricuspid Regurgitation, Is Associated With Outcome Late After Left Heart Valve Procedure. Journal of the American College of Cardiology, 2014, 64, 2633-2642.	2.8	128
77	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Annals of the Rheumatic Diseases, 2014, 73, 1340-1349.	0.9	633
78	Acute Hemodynamic Effects of Riociguat in Patients With Pulmonary Hypertension Associated With Diastolic Heart Failure (DILATE-1). Chest, 2014, 146, 1274-1285.	0.8	214
79	Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction. Circulation, 2013, 128, 502-511.	1.6	286
80	Factors Determining Patient-Prosthesis Mismatch after Aortic Valve Replacement – A Prospective Cohort Study. PLoS ONE, 2013, 8, e81940.	2.5	28
81	Non-invasive algorithms for the diagnosis of pulmonary hypertension. Thrombosis and Haemostasis, 2012, 108, 1037-1041.	3.4	8
82	Right Ventricular Load at Exercise Is a Cause of Persistent Exercise Limitation in Patients With Normal Resting Pulmonary Vascular Resistance After Pulmonary Endarterectomy. Chest, 2011, 139, 122-127.	0.8	82
83	Iloprost – different indications and different national experiences in treating pulmonary hypertension. Clinical Research in Cardiology Supplements, 2010, 5, 19-23.	2.0	0
84	Role for Staphylococci in Misguided Thrombus Resolution of Chronic Thromboembolic Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 678-684.	2.4	100
85	Predictors of Outcome in Chronic Thromboembolic Pulmonary Hypertension. Circulation, 2007, 115, 2153-2158.	1.6	263
86	Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 2005, 93, 512-516.	3.4	253
87	Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. Chest, 2005, 128, 2599-2603.	0.8	129